University of Minnesota

About: University of Minnesota is a education organization based out in Minneapolis, Minnesota, United States. It is known for research contribution in the topics: Population & Transplantation. The organization has 117432 authors who have published 257986 publications receiving 11944239 citations. The organization is also known as: University of Minnesota, Twin Cities & University of Minnesota-Twin Cities.

The epidemiology of epilepsy in Rochester, Minnesota, 1935 through 1967.

Abstract: SUMMARY Other demographic studies of epilepsy have revealed mean annual incidence rates ranging from 17/100,000 (Sato, 1964) to 70/100,000 (Pond et al., 1960) and prevalence rates from 2.8/S, OOO to as high as 15/1,000. Comprehensive review of their methods indicates that, although rates may indeed differ among different populations, a major problem is the wide variation in the completeness of case ascertainment and the definitions of epilepsy used.

Azithromycin for Prevention of Exacerbations of COPD

Abstract: A total of 1577 subjects were screened; 1142 (72%) were randomly assigned to receive azithromycin, at a dose of 250 mg daily (570 participants), or placebo (572 participants) for 1 year in addition to their usual care. The rate of 1-year follow-up was 89% in the azithromycin group and 90% in the placebo group. The median time to the first exac erbation was 266 days (95% confidence interval [CI], 227 to 313) among participants receiving azithromycin, as compared with 174 days (95% CI, 143 to 215) among par ticipants receiving placebo (P<0.001). The frequency of exacerbations was 1.48 exacerba tions per patient-year in the azithromycin group, as compared with 1.83 per patient-year in the placebo group (P = 0.01), and the hazard ratio for having an acute exacerbation of COPD per patient-year in the azithromycin group was 0.73 (95% CI, 0.63 to 0.84; P<0.001). The scores on the St. George’s Respiratory Questionnaire (on a scale of 0 to 100, with lower scores indicating better functioning) improved more in the azithro mycin group than in the placebo group (a mean [±SD] decrease of 2.8±12.8 vs. 0.6±11.4, P = 0.004); the percentage of participants with more than the minimal clinically important difference of −4 units was 43% in the azithromycin group, as compared with 36% in the placebo group (P = 0.03). Hearing decrements were more common in the azithromycin group than in the placebo group (25% vs. 20%, P = 0.04). Conclusions Among selected subjects with COPD, azithromycin taken daily for 1 year, when added to usual treatment, decreased the frequency of exacerbations and improved quality of life but caused hearing decrements in a small percentage of subjects. Although this intervention could change microbial resistance patterns, the effect of this change is not known. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT00325897.)

Group Versus Individual Training and Group Performance: The Mediating Role of Transactive Memory

Abstract: The task performance of laboratory work groups whose members were trained together or alone was investigated. At an initial training session, subjects were taught to assemble transistor radios. Some were trained in groups, others individually. A week later, subjects were asked to recall the assembly procedure and actually assemble a radio. Everyone performed these tasks in small work groups, each containing three persons of the same gender. Subjects in the group training condition worked in the same groups where they were trained, whereas subjects in the individual training condition worked in newly formed groups. Groups whose members were trained together recalled more about the assembly procedure and produced better-quality radios than groups whose members were trained alone. Through an analysis of videotape data, the mediating effects of various cognitive and social factors on the relationship between group training and performance were explored. The results indicated that group training improved group...

Predictions for the rates of compact binary coalescences observable by ground-based gravitational-wave detectors

Abstract: We present an up-to-date, comprehensive summary of the rates for all types of compact binary coalescence sources detectable by the initial and advanced versions of the ground-based gravitational-wave detectors LIGO and Virgo. Astrophysical estimates for compact-binary coalescence rates depend on a number of assumptions and unknown model parameters and are still uncertain. The most confident among these estimates are the rate predictions for coalescing binary neutron stars which are based on extrapolations from observed binary pulsars in our galaxy. These yield a likely coalescence rate of 100 Myr−1 per Milky Way Equivalent Galaxy (MWEG), although the rate could plausibly range from 1 Myr−1 MWEG−1 to 1000 Myr−1 MWEG−1 (Kalogera et al 2004 Astrophys. J. 601 L179; Kalogera et al 2004 Astrophys. J. 614 L137 (erratum)). We convert coalescence rates into detection rates based on data from the LIGO S5 and Virgo VSR2 science runs and projected sensitivities for our advanced detectors. Using the detector sensitivities derived from these data, we find a likely detection rate of 0.02 per year for Initial LIGO–Virgo interferometers, with a plausible range between 2 × 10−4 and 0.2 per year. The likely binary neutron–star detection rate for the Advanced LIGO–Virgo network increases to 40 events per year, with a range between 0.4 and 400 per year.